Literature DB >> 31497758

Pro-inflammatory Cytokines and Oxidized Low-Density-Lipoprotein in Patients With Fibromyalgia.

Funda Canpolat Kutu1, Şenay Özdolap2, Selda Sarikaya2.   

Abstract

OBJECTIVES: This study aims to evaluate the differences in serum levels of tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), (IL-8), and oxidized low-density lipoprotein (Ox-LDL) between female fibromyalgia (FM) patients and healthy females and also to examine a possible relationship between the cytokines/biomarker and the severity of pain and clinical features of FM. PATIENTS AND METHODS: This case-control study included 48 female patients (mean age 26.51±6.98 years; range, 18 to 50 years) who were diagnosed with FM according to the American College of Rheumatology criteria and 43 healthy female subjects (mean age 23.93±4.22 years; range, 18 to 50 years). Serum levels of TNF-α, IL-1β, IL-8, and Ox-LDL were measured by enzyme-linked immunosorbent assay in both groups. Fibromyalgia Impact Questionnaire, Visual Analog Scale, symptom severity scale, and widespread pain index were carried out and also their relationships with TNF-α, IL-1β, IL-8, and Ox-LDL levels were evaluated.
RESULTS: There was no difference in levels of the serum TNF-α, IL-1β, IL-8, and Ox-LDL between FM patients and healthy controls (p>0.05). The severity of pain was significantly associated with TNF-α (r=0.338; p=0.021) and IL-8 (r=0.299; p=0.043) levels, and Ox-LDL (r=0.415; p=0.006) level was found to be related to symptom severity of FM.
CONCLUSION: Our results suggest that serum levels of TNF-α and IL-8 may be involved in the occurrence of pain in FM. The level of Ox-LDL may play an important role in the severity of symptoms. Future studies are needed to determine whether and how Ox-LDL plays a role in FM.

Entities:  

Keywords:  Cytokines; fibromyalgia; oxidative stress; oxidized-low-density lipoprotein; pain

Year:  2018        PMID: 31497758      PMCID: PMC6719580          DOI: 10.5606/ArchRheumatol.2019.6733

Source DB:  PubMed          Journal:  Arch Rheumatol        ISSN: 2148-5046            Impact factor:   1.472


  32 in total

1.  Cytokine patterns in fibromyalgia and their correlation with clinical manifestations.

Authors:  L Bazzichi; A Rossi; G Massimetti; G Giannaccini; T Giuliano; F De Feo; A Ciapparelli; L Dell'Osso; S Bombardieri
Journal:  Clin Exp Rheumatol       Date:  2007 Mar-Apr       Impact factor: 4.473

2.  Reduced levels of antiinflammatory cytokines in patients with chronic widespread pain.

Authors:  Nurcan Uçeyler; Regine Valenza; Michael Stock; Robert Schedel; Günter Sprotte; Claudia Sommer
Journal:  Arthritis Rheum       Date:  2006-08

3.  Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study.

Authors:  D J Wallace; M Linker-Israeli; D Hallegua; S Silverman; D Silver; M H Weisman
Journal:  Rheumatology (Oxford)       Date:  2001-07       Impact factor: 7.580

4.  Antioxidant status, lipid peroxidation and nitric oxide in fibromyalgia: etiologic and therapeutic concerns.

Authors:  Salih Ozgocmen; Huseyin Ozyurt; Sadik Sogut; Omer Akyol; Ozge Ardicoglu; Hulya Yildizhan
Journal:  Rheumatol Int       Date:  2005-11-10       Impact factor: 2.631

5.  The validity and reliability of the Turkish version of the Fibromyalgia Impact Questionnaire.

Authors:  S Sarmer; S Ergin; G Yavuzer
Journal:  Rheumatol Int       Date:  2000-12       Impact factor: 2.631

6.  Cytokines and depression in cases with fibromyalgia.

Authors:  Ali Gür; Mehmet Karakoç; Kemal Nas; Aziz Denli; Jale Saraç
Journal:  J Rheumatol       Date:  2002-02       Impact factor: 4.666

Review 7.  Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment.

Authors:  Philip Mease
Journal:  J Rheumatol Suppl       Date:  2005-08

Review 8.  TNF-mediated inflammatory disease.

Authors:  J R Bradley
Journal:  J Pathol       Date:  2008-01       Impact factor: 7.996

9.  Circulating cytokine levels compared to pain in patients with fibromyalgia -- a prospective longitudinal study over 6 months.

Authors:  Haili Wang; Michael Moser; Marcus Schiltenwolf; Matthias Buchner
Journal:  J Rheumatol       Date:  2008-06-01       Impact factor: 4.666

10.  Regional cerebral blood flow and cytokines in young females with fibromyalgia.

Authors:  A Gur; M Karakoc; S Erdogan; K Nas; R Cevik; A J Sarac
Journal:  Clin Exp Rheumatol       Date:  2002 Nov-Dec       Impact factor: 4.473

View more
  4 in total

Review 1.  Pain Control by Targeting Oxidized Phospholipids: Functions, Mechanisms, Perspectives.

Authors:  Beatrice Oehler; Alexander Brack; Robert Blum; Heike L Rittner
Journal:  Front Endocrinol (Lausanne)       Date:  2021-01-25       Impact factor: 5.555

Review 2.  Application of Salivary Biomarkers in the Diagnosis of Fibromyalgia.

Authors:  Rebeca Illescas-Montes; Víctor J Costela-Ruiz; Lucía Melguizo-Rodríguez; Elvira De Luna-Bertos; Concepción Ruiz; Javier Ramos-Torrecillas
Journal:  Diagnostics (Basel)       Date:  2021-01-03

3.  Gentle Touch Therapy, Pain Relief and Neuroplasticity at Baseline in Fibromyalgia Syndrome: A Randomized, Multicenter Trial with Six-Month Follow-Up.

Authors:  Afonso Shiguemi Inoue Salgado; Miriam Hatsue Takemoto; Carla Fernanda Tallarico Carvalho de Souza; Daiana Cristina Salm; Danielli da Rosa; Gabriela Correa Cardoso; Daniela Dero Ludtke; Silvia Fiorillo Cabrera Soares; Júlia Koerich Ferreira; Aline Raulino Dutra; Yuri Cordeiro Szeremeta; Gustavo Mazzardo; Joice Mayra; Débora da Luz Sheffer; Wolnei Caumo; Edsel B Bittencourt; Robert Schleip; Alexandra Latini; Franciane Bobinski; Daniel Fernandes Martins
Journal:  J Clin Med       Date:  2022-08-20       Impact factor: 4.964

Review 4.  Fibromyalgia: practical considerations for oral health care providers.

Authors:  Younghoon Jeon
Journal:  J Dent Anesth Pain Med       Date:  2020-10-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.